Dopaminergic dysregulation syndrome in Parkinson's disease

Journal of the Neurological Sciences

Volumn 310, Issue 1-2, 2011, Pages 271-275

  Katzenschlager, Regina ^a  

^a DANUBE HOSPITAL   (Austria)

Author keywords

Behavioural disorders; Dopaminergic dysregulation syndrome; Impulse control disorders; Parkinson's disease; Punding

Indexed keywords

LEVODOPA;

ARTICLE; BEHAVIOR DISORDER; CLINICAL FEATURE; COMPULSION; DOPAMINERGIC ACTIVITY; DOPAMINERGIC DYSREGULATION SYNDROME; DOPAMINERGIC SYSTEM; DRUG USE; HABIT; HEREDITY; IMPULSE CONTROL DISORDER; PARKINSON DISEASE; PERSONALITY; PERSONNEL MANAGEMENT; PRIORITY JOURNAL; RISK FACTOR; SENSITIZATION;

ANTIPARKINSON AGENTS; BEHAVIORAL SYMPTOMS; DOPAMINE; DOPAMINE AGONISTS; HUMANS; IMPULSE CONTROL DISORDERS; PARKINSON DISEASE;

EID: 80054104406     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2011.07.012     Document Type: Article

References (47)

1. P.A. Nausieda Sinemet "abusers" Clin Neuropharmacol 8 1985 318 327
2. S. Priebe Levodopa dependence: a case report Pharmacopsychiatry 17 1984 109 110 (Pubitemid 14089044)
3. O. Spigset, and C. von Schéele Levodopa dependence and abuse in Parkinson's disease Pharmacotherapy 17 1997 1027 1030 (Pubitemid 27415108)
4. G. Giovannoni, J.D. O'Sullivan, K. Turner, A.J. Manson, and A.J. Lees Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies J Neurol Neurosurg Psychiatry 68 2000 423 428 (Pubitemid 30248740)
5. A.H. Evans, A.D. Lawrence, J. Potts, S. Appel, and A.J. Lees Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson disease Neurology 65 2005 1570 1574 (Pubitemid 41689470)
6. S. ÓSullivan, A.H. Evans, and A.J. Lees Dopamine dysregulation syndrome. an overview of its epidemiology, mechanisms and management CNS Drugs 23 2009 157 170
7. D.A. Gallagher, S.S. O'Sullivan, A.H. Evans, A.J. Lees, and A. Schrag Pathological gambling in Parkinson's disease: risk factors and differences from dopamine dysregulation. An analysis of published case series Mov Disord 22 2007 1757 1763 (Pubitemid 47597599)
8. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 1994 American Psychiatric Press Washington, DC
9. D. Weintraub, J. Koester, M.N. Potenza, A.D. Siderowf, M. Stacy, and V. Voon Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients Arch Neurol 67 2010 589 595
10. A.H. Evans, R. Katzenschlager, D. Paviour, J.D. O'Sullivan, S. Appel, and A.D. Lawrence Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome Mov Disord 19 2004 397 405 (Pubitemid 38559642)
11. V. Voon, T. Thomsen, J.M. Miyasaki, M. de Souza, A. Shafro, and S.H. Fox Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease Arch Neurol 64 2007 212 216
12. F.R. Pezzella, C. Colosimo, and N. Vanacore Prevalence and clinical features of hedonistic homeostatic dysregulation in Parkinson's disease Mov Disord 20 2005 77 81 (Pubitemid 40277510)
13. A.H. Evans, A.D. Lawrence, S.A. Cresswell, R. Katzenschlager, and A.J. Lees Compulsive use of dopaminergic drug therapy in Parkinson's disease: reward and anti-reward Mov Disord 25 2010 867 876
14. A.H. Evans, N. Pavese, A.D. Lawrence, J.D. O'Sullivan, S. Appel, and A.D. Lawrence Compulsive drug use linked to sensitized ventral striatal dopamine transmission Ann Neurol 59 2006 852 858 (Pubitemid 43673163)
15. W. Gerschlager, and B.R. Bloem Managing pathological gambling in Parkinson's disease with enteral levodopa/carbidopa infusions Mov Disord 24 2009 1858 1860
16. M.J. Kreek, D.A. Nielsen, E.R. Butelman, and K.S. LaForge Genetic influences on impulsivity, risk taking, stress responsivity and vulnerability to drug abuse and addiction Nat Neurosci 8 2005 1450 1457 (Pubitemid 41573655)
17. R. Cilia, S.S. Cho, T. van Eimeren, G. Marotta, C. Siri, and J.H. Ko Pathological gambling in patients with Parkinson's disease is associated with fronto-striatal disconnection: a path modeling analysis Mov Disord 26 2011 225 233
18. T. van Eimeren, O. Monchi, B. Ballanger, and A.P. Strafella Dysfunction of the default mode network in Parkinson disease: a functional magnetic resonance imaging study Arch Neurol 66 2009 877 883
19. N. Ray, and A.P. Strafella Dopamine, reward, and frontostriatal circuitry in impulse control disorders in Parkinson's disease: insights from functional imaging Clin EEG Neurosci 41 2010 87 93
20. A. Djamshidian, A. Jha, S.S. O'Sullivan, L. Silveira-Moriyama, L. Silveira-Moriyama, and C. Jacobson Risk and learning in impulsive and nonimpulsive patients with Parkinson's disease Mov Disord 25 2010 2203 2210
21. G. Santangelo, C. Vitale, L. Trojano, F. Verde, D. Grossi, and P. Barone Cognitive dysfunctions and pathological gambling in patients with Parkinson's disease Mov Disord 30 24 2009 899 905
22. V. Voon, B. Reynolds, C. Brezing, C. Gallea, M. Skaljic, and V. Ekanayake Impulsive choice and response in dopamine agonist-related impulse control behaviors Psychopharmacology 207 2010 645 659
23. L. Ishihara, and C. Brayne What is the evidence for a premorbid parkinsonian personality: a systematic review Mov Disord 21 2006 1066 1072 (Pubitemid 44336588)
24. P. Schwingenschuh, P. Katschnig, R. Saurugg, E. Ott, and K.P. Bhatia Artistic profession: a potential risk factor for dopamine dysregulation syndrome in Parkinson's disease? Mar Mov Disord 25 2010 493 496
25. A. Kummer, D.P. Maia, J.V. Salgado, F.E. Cardoso, and A.L. Teixeira Dopamine dysregulation syndrome in Parkinson's disease: case report Arq Neuropsiquiatr 64 2006 1019 1022 (Pubitemid 46120176)
26. R. Kurlan Disabling repetitive behaviors in Parkinson's disease Mov Disord 19 2004 433 437 (Pubitemid 38559646)
27. J.L. Houeto, V. Mesnage, L. Mallet, B. Pillon, M. Gargiulo, and S.T. du Moncel Behavioural disorders, Parkinson's disease and subthalamic stimulation J Neurol Neurosurg Psychiatry 72 2002 701 707 (Pubitemid 34557009)
28. S.Y. Lim, M. Zurowski, and E. Moro Impulsive-compulsive behaviours and subthalamic nucleus deep brain stimulation in Parkinson's disease Eur Neurol J 2 2 2010
29. P. Krack, A. Batir, N. Van Blercom, S. Chabardes, V. Fraix, and C. Ardouin Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease N Engl J Med 349 2003 1925 1934 (Pubitemid 37409709)
30. T. Witjas, C. Baunez, J.M. Henry, M. Delfini, J. Regis, and A.A. Cherif Addiction in Parkinson's disease: impact of subthalamic nucleus deep brain stimulation Mov Disord 20 2005 1052 1055 (Pubitemid 41419526)
31. F. Bandini, A. Primavera, M. Pizzorno, and L. Cocito Using STN DBS and medication reduction as a strategy to treat pathological gambling in Parkinson's disease Parkinsonism Relat Disord 13 2007 369 371 (Pubitemid 47212785)
32. D. Knobel, S. Aybek, C. Pollo, F.J. Vingerhoets, and A. Berney Rapid resolution of dopamine dysregulation syndrome (DDS) after subthalamic DBS for Parkinson disease (PD): a case report Cogn Behav Neurol 21 2008 187 189
33. S.Y. Lim, S.S. O'Sullivan, K. Kotschet, D.A. Gallagher, C. Lacey, and A.D. Lawrence Dopamine dysregulation syndrome, impulse control disorders and punding after deep brain stimulation surgery for Parkinson's disease J Clin Neurosci 16 2009 1148 1152
34. W.M. Schüpbach, N. Chastan, M.L. Welter, J.L. Houeto, V. Mesnage, and A.M. Bonnet Stimulation of the subthalamic nucleus in Parkinson's disease: a 5 year follow up J Neurol Neurosurg Psychiatry 76 2005 1640 1644 (Pubitemid 41697626)
35. V. Voon, P. Krack, A.E. Lang, A.M. Lozano, K. Dujardin, and M. Schüpbach A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson's disease Brain 131 2008 2720 2728
36. E. Mamikonyan, A.D. Siderowf, J.E. Duda, M.N. Potenza, S. Horn, and M.B. Stern Long-term follow-up of impulse control disorders in Parkinson's disease Mov Disord 23 2008 75 80 (Pubitemid 351281221)
37. D. Benincasa, C. Pellicano, A. Fanciulli, and F. Pontieri Bupropion abates dopamine agonist-mediated compulsive behaviors in Parkinson's disease Mov Disord 26 2011 355 357
38. A. Thomas, L. Bonanni, F. Gambi, A. Di Iorio, and M. Onofrj Pathological gambling in Parkinson disease is reduced by amantadine Ann Neurol 68 2010 400 404
39. D. Weintraub, M. Sohr, M.N. Potenza, A.D. Siderowf, M. Stacy, and V. Voon Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study Ann Neurol 68 2010 963 968
40. P.E. Bermejo Topiramate in managing impulse control disorders in Parkinson's disease Parkinsonism Relat Disord 14 2008 448 449
41. P.E. Bermejo, C. Ruiz-Huete, and B. Anciones Zonisamide in managing impulse control disorders in Parkinson's disease J Neurol 257 2010 1682 1685
42. A. Fasano, L. Ricciardi, M. Pettorruso, and A.R. Bentivoglio Management of punding in Parkinson's disease: an open-label prospective study J Neurol 258 2011 656 660
43. K. Kashihara, and T. Imamura Amantadine may reverse punding in Parkinson's disease-observation in a patient Mov Disord 23 2008 129 130 (Pubitemid 351281231)
44. H.H. Fernandez, and J.H. Friedman Punding on l-dopa Mov Disord 14 1999 836 838
45. S. Kumar Punding in Parkinson's disease related to high-dose levodopa therapy Neurol India 53 2005 362 (Pubitemid 41526861)
46. H. Miwa, S. Morita, I. Nakanishi, and T. Kondo Stereotyped behaviors or punding after quetiapine administration in Parkinson's disease Parkinsonism Relat Disord 10 2004 177 180 (Pubitemid 38251663)
47. A.H. Spencer, H. Rickards, A. Fasano, and A.E. Cavanna The prevalence and clinical characteristics of punding in Parkinson's disease Mov Disord 26 2011 578 586